CLINICAL EVALUATION OF LEVONORGESTREL BUTANOATE FOR FEMALE CONTRACEPTION

左炔诺孕酮丁酸酯对女性避孕的临床评价

• 批准号: 8331041
• 负责人: MICHAEL THOMAS
• 金额: $ 7.24万
• 依托单位: UNIVERSITY OF CINCINNATI
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-03-31 至 2013-03-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8331041
• 关键词: Adverse effects; Age; Antral; Blood specimen; Cervix Mucus; Chlamydia; Clinical; Clinical Chemistry; Clinical Trials; Contraceptive Agents; Contraceptive methods; Data; Development; Dose; Drug Formulations; Drug Kinetics; Endometrial; Enrollment; Estrogens; Evaluation; Female Contraceptions; Goals; Gonorrhea; Hematology; Hemorrhage; Hormones; Human Chorionic Gonadotropin; Implant; Injectable; Injection of therapeutic agent; Intrauterine Devices; Levonorgestrel; Measurement; Medical; Medical History; Menstruation; Non obese; Obesity; Ovarian; Ovulation Inhibition; Pap smear; Pattern; Phase; Population; Pregnancy Tests; Progesterone; Protocols documentation; Recording of previous events; Risk; Safety; Sampling; Screening procedure; Serum; Thromboembolism; Ultrasonography; Urine; Venous; Visit; Woman; contraceptive effectiveness; contraceptive efficacy; follow-up; peripheral blood; pill; protocol development; reproductive; research clinical testing

There is a demand for estrogen-free contraception in order to reduce the risk of venous thromboembolism (VTE), particularly of obese women. A new long acting formulation of Levonorgestrel Butanoate (LB), delivered by injection, has been developed. Levonorgestrel (LNG) has a long history of clinical use in a variety of contraceptives (pills, intrauterine devices, and implants) and its efficacy and safety are well recognized.

为了降低静脉血栓栓塞（VTE）的风险，特别是肥胖女性，需要无雌激素避孕药。一种新的长效左炔诺孕酮丁酸酯 (LB) 注射剂型已开发出来。左炔诺孕酮 (LNG) 在各种避孕药具（丸剂、宫内节育器和埋植剂）中有着悠久的临床应用历史，其功效和安全性得到了广泛认可。